These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23723125)

  • 1. Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib.
    Zhang M; Taylor CE; Piao L; Datta J; Bruno PA; Bhave S; Su T; Lang JC; Xie X; Teknos TN; Mapp AK; Pan Q
    Mol Cancer Ther; 2013 Aug; 12(8):1515-25. PubMed ID: 23723125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
    Zhang M; Piao L; Datta J; Lang JC; Xie X; Teknos TN; Mapp AK; Pan Q
    Mol Cancer Ther; 2015 Oct; 14(10):2313-20. PubMed ID: 26227488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
    Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
    Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
    Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W
    Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
    De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
    Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
    Weisheit S; Liebmann C
    Cell Signal; 2012 Feb; 24(2):422-434. PubMed ID: 21964064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
    Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
    Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
    Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
    Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
    Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
    Fletcher EV; Love-Homan L; Sobhakumari A; Feddersen CR; Koch AT; Goel A; Simons AL
    Mol Cancer Res; 2013 Dec; 11(12):1574-84. PubMed ID: 24048704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
    Sun Q; Ming L; Thomas SM; Wang Y; Chen ZG; Ferris RL; Grandis JR; Zhang L; Yu J
    Oncogene; 2009 Jun; 28(24):2348-57. PubMed ID: 19421143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
    Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin.
    Brands RC; Müller-Richter UD; De Donno F; Seher A; Mutzbauer G; Linz C; Kübler AC; Hartmann S
    Mol Med Rep; 2016 Mar; 13(3):2338-44. PubMed ID: 26782932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.
    Rao VH; Kandel A; Lynch D; Pena Z; Marwaha N; Deng C; Watson P; Hansen LA
    Oncogene; 2012 Jun; 31(23):2888-98. PubMed ID: 21986939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
    Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
    Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
    Tsai YC; Ho PY; Tzen KY; Tuan TF; Liu WL; Cheng AL; Pu YS; Cheng JC
    Mol Cancer Ther; 2015 Mar; 14(3):810-20. PubMed ID: 25589492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
    Oliveras-Ferraros C; Massaguer Vall-Llovera A; Carrion Salip D; Vazquez-Martin A; Cufí S; Queralt B; Martin-Castillo B; Brunet J; de Llorens R; Menendez JA
    Invest New Drugs; 2012 Apr; 30(2):846-52. PubMed ID: 21161326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.